Home Hemophilia
This page is made to present regional, national and international collaborative project currently involving Defymed.
Hemophilia is an inherited disorder caused by low or deficient level of clotting factor/s leading to the inability to form proper blood clot. This deficiency is caused by genetic mutations on the X chromosome encoding both clotting factors VIII (FVIII) and IX (FIX).
There are two main kinds of Hemophilia that depend on the type of missing factor:
Approximately % 50
of people with Hemophilia around the world still receive inadequate treatment or have no access to treatment
More than $ 199950
treatment costs encompasses per patient per year, including indirect costs
Approximately % 1
of patients with severe form of Hemophilia will develop inhibitors against injected factors
Rare inherited disorder (genetic mutations on the X chromosome)
2 mains types : hemophilia A (factor VIII) and B (factor IX)
Low or deficient levels of clotting factors
3 forms depending on clotting factor level : severe, moderate, mild
One injection of factors every 2-3 days= prophylactic treatment
Spontaneous bleeding is the most dangerous complication
The goal of Defymed is to use MailPan® technology as a platform for cell encapsulation. In the case of Hemophilia A, the aim is to macro-encapsulate factor VIII secreting cells in immuno-protective membrane.
The combined solution implies and offers: